



Announcement Summary

---

**Entity name**

AUSTRALIAN PHARMACEUTICAL INDUSTRIES LIMITED

**Date of this announcement**

Monday November 08, 2021

**The +securities the subject of this notification are:**

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

**Total number of +securities to be issued/transferred**

<b>ASX +security code</b>	<b>Security description</b>	<b>Total number of +securities to be issued/transferred</b>	<b>Issue date</b>
APIAA	PERFORMANCE RIGHTS VARIOUS EXPIRIES	1,555,500	04/11/2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

AUSTRALIAN PHARMACEUTICAL INDUSTRIES LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

**1.2 Registered number type**

ABN

**Registration number**

57000004320

**1.3 ASX issuer code**

API

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

8/11/2021



Part 2 - Issue details

---

**2.1 The +securities the subject of this notification are:**

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

**2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:**

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

**Additional +securities in an existing class issued under an +employee incentive scheme**

**ASX +security code and description**

APIAA : PERFORMANCE RIGHTS VARIOUS EXPIRIES

**Date the +securities the subject of this notification were issued**

4/11/2021

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Peter Mendo	Peter Mendo	209,580

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

The terms of the API Long Term Incentive Plan are summarised in the API Remuneration Report which is contained in API's Appendix 4E and FY21 Financial Report which can be found here: <https://www.api.net.au/wp-content/uploads/2021/10/Appendix-4E-and-FY21-Financial-Report.pdf>

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Issue details

**Number of +securities**

1,555,500



Part 4 - +Securities on issue

---

**Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:  
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)**

**4.1 Quoted +Securities (Total number of each +class of +securities quoted)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
API : ORDINARY FULLY PAID	492,656,035

**4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
APIAA : PERFORMANCE RIGHTS VARIOUS EXPIRIES	5,879,621



Part 5 - Other Listing Rule requirements

---

**5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?**

No

**5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

No

**5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

Yes

**5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

1,555,500 Performance Rights

**5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

No